1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy. ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The ideal efficacy of an ADC is entirely dependent on … Read more
So far, more than 10 types of antibody-drug conjugates (ADC) have been approved by the U.S. Food and Drug Administration (FDA) and have contributed to the medical field. Interestingly, they are all manufactured using chemical conjugation techniques. This indicates that chemical conjugation is the primary method for ADC manufacturing. Compared to other conjugation techniques such … Read more
Compiled by: Oncology Information Source: Oncology Information Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with cytotoxic small molecule drugs, combining the targeting specificity of antibody drugs with the powerful lethality of cytotoxins. The aim is to overcome the issues of weak cytotoxicity of monoclonal antibodies and the high toxicity … Read more
What is Functional Magnetic Resonance Imaging? Various magnetic resonance imaging techniques based primarily on conventional T1WI and T2WI mainly display the morphological structures of human organs or tissues and their signal intensity changes, collectively referred to as conventional MRI examinations or conventional MR imaging sequences. With the development of MRI system hardware and software, various … Read more
Since the end of 2019 and the beginning of 2020, I have been looking at ADCs, and I have discussed with many experts in the field, leading to many misunderstandings, and my understanding has been continuously refreshed. Many articles about ADCs exist, but many of them contain misunderstandings. Now, there are more successful and failed … Read more
Antibody-drug conjugates (ADCs) have become a popular avenue for cancer treatment in recent years. They typically consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs (payloads) through chemically synthesized linkers. ADCs combine the advantages of high specificity targeting and effective killing action, achieving precise and efficient elimination of cancer cells. Figure 1. Structure and … Read more
Introduction: Antibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule cytotoxic drugs, combining high specificity and high cytotoxicity advantages. However, their structural diversity and complexity, along with the low content of released small molecule toxins in the circulatory system, pose significant challenges for pharmacokinetic studies. This article will discuss the mechanisms, design, safety features, … Read more
Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more
ADC In the era following chemotherapy, targeted therapy, and immunotherapy, ADC drugs, which combine cytotoxic drugs with targeted monoclonal antibodies, have opened a new era of fourth-line cancer treatment with exceptional results. They have become a significant class of new drugs in cancer treatment both domestically and internationally. So, what are ADC drugs (antibody-drug conjugates)? … Read more
Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more